Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund

This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

CII elects R Mukundan as President for 2026-27, Suchitra K Ella named President-Designate

Shashwat Goenka takes over as Vice President of industry body

Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India

Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence

Altasciences and Certara forge strategic pact to speed early drug development

P. D. Hinduja Hospital introduces CORI robotic-assisted system for knee and hip replacement

Advanced image-free robotic platform to support greater precision, personalised planning, and improved patient outcomes

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

Computational tool ‘Renoir’ to decode cell communication in complex tissues

IIT Kanpur team has developed computational framework to map how cell signals influence gene activity across tissues

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Shareholders approve J.B. Pharma merger with Torrent Pharma

Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held